17,261 trials
Cervical Cancer · Endometrial Cancer
Primary: Reproducibility of Radiation Technique (Number of Unacceptable Deviations in Central IMRT Quality Assurance Review) — 1; 0 participants
Skin Cancer · Melanoma · Metastatic Melanoma
Primary: Response Rate — 0; 0; 1; 1 Participants
Epilepsy · Seizure Disorders
Primary: 50% Responder Rate — 40.5; 15.6 percentage of participants
Type 2 Diabetes
Primary: Change From Baseline in HbA1c at Week 12 — 0.11; -0.77; -0.80; -0.91 Percent
Hematologic Malignancies
Primary: Overall Survival of Participants — 13 participants
HIV -1 Infection · HIV Infections
Primary: Maximum Change in Viral Load Following Initiation of Treatment (Viral Load is Defined as HIV-1 Copies/mL and Expressed as log10 Copies/mL). — -0.99; -1.65; -1.37; -0.23…
Multiple Myeloma
Primary: Response — 42 participants
Stress, Psychological · Coping Behavior
Primary: Coping Strategy: Domain Social Support(After 60 Days) — 8.81; 8.73; 11.32 units on a scale — p=0,022
HIV Infections
Primary: Maximum Change in Viral Load Following Initiation of Treatment. — -1.67; -1.83; -0.32 Log10copies HIV-1 RNA/mL
Irritable Bowel Syndrome Constipation Predominant
Primary: Colonic Transit, Colonic Geometric Center at 24 Hours — 2.39; 2.37; 2.02; 1.76 units on a scale
Crohn's Disease
Primary: Number of Patients Reporting Side Effects — 2; 2; 0; 2 participants — p=1.0
Anal Cancer
Primary: Percentage of Subjects With Acute Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) ≥ Grade 2 as Defined by CTCAE v3.0 (Common Terminology Criteria for…
Autism
Primary: Change in TNF-alpha Levels — 57 mean % change
Malaria
Primary: Number of Subjects With Serious Adverse Events (SAEs). — 38; 28; 33 subjects
Melanoma · Malignant Melanoma · Melanoma, Experimental
Primary: Clinical Response — 1; 3; 3; 2 Participants